IP Verse

Pyridone Compound As C-Met Inhibitor - EP3533787

The patent EP3533787 was granted to Fujian Cosunter Pharmaceutical on Sep 30, 2020. The application was originally filed on Oct 27, 2017 under application number EP17864813A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3533787

FUJIAN COSUNTER PHARMACEUTICAL
Application Number
EP17864813A
Filing Date
Oct 27, 2017
Status
Opposition Rejected
May 9, 2025
Grant Date
Sep 30, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MERCK PATENTJun 30, 2021MEWBURN ELLISADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONWO2008103277
OPPOSITIONWO2009006959
SEARCHWO2010072296

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- BENZ EJ JR., "The Jeremiah Metzger Lecture Cancer in the Twenty-First Century: An Inside View from an Outsider", Trans Am Clin Climatol Assoc, (20170000), vol. 128, pages 275 - 297, XP055823203
OPPOSITION- Caterina Barillari and Nathan Brown, "Classical Bioisosteres", Caterina Barillari and Nathan Brown, NATHAN BROWN, Bioisosteres in Medicinal Chemistry, pages 15 - 29, XP055823176
OPPOSITION- GARBER, K., "MET inhibitors start on road to recovery", Nat Rev Drug Discov, (20140000), vol. 13, pages 563 - 565, XP055823205
OPPOSITION- KUBIK S. et al., "Bioisosterie, RD-02-03672", RÖMPP, Stuttgart, (20120000), pages 1 - 4, URL: https://roempp.thieme.de/lexicon/RD-02-03672, XP055823191
OPPOSITION- STEINHILBER, D. et al., "Chapter 1", Medizinische Chemie - Targets, Arzneistoffe, Chemische Biologie, Stuttgart, (20000000), pages 12 - 13, XP055823199
SEARCH- SOLANGE PETERS ET AL, "MET: a promising anticancer therapeutic target", NATURE REVIEWS CLINICAL ONCOLOGY, NY, US, (20120508), vol. 9, no. 6, doi:10.1038/nrclinonc.2012.71, ISSN 1759-4774, pages 314 - 326, XP055626782 [A] 1-17 * EMD-1214063 = tepotinib;; table 2 * * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents